AU2003244452A1 - Method of promoting neuronal growth - Google Patents

Method of promoting neuronal growth

Info

Publication number
AU2003244452A1
AU2003244452A1 AU2003244452A AU2003244452A AU2003244452A1 AU 2003244452 A1 AU2003244452 A1 AU 2003244452A1 AU 2003244452 A AU2003244452 A AU 2003244452A AU 2003244452 A AU2003244452 A AU 2003244452A AU 2003244452 A1 AU2003244452 A1 AU 2003244452A1
Authority
AU
Australia
Prior art keywords
neuronal growth
promoting neuronal
promoting
growth
neuronal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003244452A
Other languages
English (en)
Inventor
Andrew Foley
Helen Gallagher
James Hagan
Ciaran Regan
Neil Upton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0202680A external-priority patent/GB0202680D0/en
Priority claimed from GB0222616A external-priority patent/GB0222616D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2003244452A1 publication Critical patent/AU2003244452A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003244452A 2002-02-05 2003-02-04 Method of promoting neuronal growth Abandoned AU2003244452A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0202680A GB0202680D0 (en) 2002-02-05 2002-02-05 Novel method
GB0202680.5 2002-02-05
GB0222616.5 2002-09-30
GB0222616A GB0222616D0 (en) 2002-09-30 2002-09-30 Novel method
PCT/GB2003/000462 WO2003066056A1 (en) 2002-02-05 2003-02-04 Method of promoting neuronal growth

Publications (1)

Publication Number Publication Date
AU2003244452A1 true AU2003244452A1 (en) 2003-09-02

Family

ID=27736189

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003244452A Abandoned AU2003244452A1 (en) 2002-02-05 2003-02-04 Method of promoting neuronal growth

Country Status (5)

Country Link
US (1) US20070270432A1 (enExample)
EP (1) EP1471912A1 (enExample)
JP (1) JP2005522432A (enExample)
AU (1) AU2003244452A1 (enExample)
WO (1) WO2003066056A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039127A1 (es) 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
EA009367B1 (ru) 2002-12-18 2007-12-28 Сувен Лайф Сайенсиз Лимитед ПРОИЗВОДНЫЕ 5-ТИА-5-ДИОКСО-4b-АЗАИНДЕНО[2,1-a]ИНДЕНА, ОБЛАДАЮЩИЕ АФФИННОСТЬЮ К РЕЦЕПТОРУ СЕРОТОНИНА
RS20060035A (sr) 2003-07-22 2008-08-07 Arena Pharmaceuticals Inc., Derivati diaril i arilheteroaril uree kao modulatori receptora 5-ht2a serotonina korisni u profilaksi i lečenju poremećaja u vezi sa njima
HRP20090419T1 (hr) 2004-01-02 2009-09-30 Suven Life Sciences Limited Novi indeno[2,1a]indeni i izoindol[2,1-a]indoli
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
BRPI0520579B8 (pt) 2005-08-12 2021-05-25 Suven Life Sciences Ltd composto, processo para a preparação de um composto e composição farmacêutica
WO2007020654A1 (en) 2005-08-16 2007-02-22 Suven Life Sciences An improved process for the preparation of losartan
DK2114878T3 (da) 2007-01-08 2011-03-14 Suven Life Sciences Ltd 5-(Heterocyclyl)alkyl-N-(arylsulfonyl)indolforbindelser og deres anvendelse som 5-HT6-ligander
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
WO2008136017A1 (en) 2007-05-03 2008-11-13 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
EP2200980B9 (en) 2007-10-26 2011-12-28 Suven Life Sciences Limited Amino arylsulfonamide compounds and their use as 5-ht6 ligands field of invention
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
EA019496B1 (ru) 2008-09-17 2014-04-30 Сувен Лайф Сайенсиз Лимитед Арилсульфонамидные аминосоединения и их применение в качестве лигандов 5-ht
WO2010032257A1 (en) 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
NZ601284A (en) 2010-01-05 2014-03-28 Suven Life Sciences Ltd Sulfone compounds as 5-ht6 receptor ligands
KR101608499B1 (ko) 2013-10-08 2016-04-01 이화여자대학교 산학협력단 4-니트로인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 5-ht6 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
AU2016276966A1 (en) 2015-06-12 2018-01-18 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder
EP3322415A4 (en) 2015-07-15 2019-03-13 Axovant Sciences GmbH DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR FOR PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS RELATED TO A NEUROGENERATIVE DISEASE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.

Also Published As

Publication number Publication date
EP1471912A1 (en) 2004-11-03
JP2005522432A (ja) 2005-07-28
US20070270432A1 (en) 2007-11-22
WO2003066056A1 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
AU2003291352A1 (en) Method of securing vertebrae
AU2003244452A1 (en) Method of promoting neuronal growth
AU2003239489A1 (en) Method of treating dyslipidemic disorders
AU2003282558A1 (en) Nanopellets and method of making nanopellets
AU2003277596A1 (en) Method of deuterization
AU2003258070A1 (en) Electrodionization method
AU2003233820A1 (en) Method for the treatment of starch
AU2003276284A1 (en) Method for inhibiting yeast growth
AUPS096002A0 (en) Method of construction
AU2003262911A1 (en) Methods of promoting osteogenesis
AU2003234921A1 (en) Method of knitting knit-wear
AU2003221005A1 (en) Method of wastewater treatment
AU2002951913A0 (en) Method of treatment
AU2003226871A1 (en) Pearl culture method
AU2003222584A1 (en) Method of producing organoacyloxysilanes
AU2003278535A1 (en) Histoscreen method
AU2003246737A1 (en) Antimicrobial coatings and method for production thereof
AU2003233239A1 (en) Method for the production of polymethylenepolysulfides
AU2003296180A1 (en) Method for purification of milbemycins
AU2003290512A1 (en) Method of weldbonding
AU2003255785A1 (en) Method of authentication
AUPS230702A0 (en) A method of treatment
AU2002953042A0 (en) Method of treatment
AUPS079602A0 (en) Method of treatment
AU2002950351A0 (en) Method of Treatment-III

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase